LPL and metabolic dysfunction-associated steatotic liver disease: Additional factors involved in the pathogenesis of MASLD include increased levels of endogenous lipoprotein lipase (Lpl) inhibitors, with a decreased clearance ability of circulating triglyceride-enriched lipoproteins by Lpl [113].